Treatment
Share your love
FDA Reviews Aldeyra’s Dry Eye Drug
Aldeyra Therapeutics has announced a major milestone as the FDA formally accepted its resubmitted New Drug Application (NDA) for reproxalap, a topical ocular therapy for the treatment of dry eye disease. Alongside this regulatory progress, Aldeyra has expanded its exclusive…
OBN Spotlight TV: Interview with Hillary A. Golden
In late October, Medicare introduced proposed Local Coverage Determinations (LCDs) that aimed to impose restrictions on Minimally Invasive Glaucoma Surgery (MIGS) procedures. These LCDs were met with significant concern and opposition from medical professionals, patient advocacy groups, and the ophthalmology…
Innovations in Dry Eye Testing: New Diagnostic Tools
Dry eye disease (DED), also known as keratoconjunctivitis sicca, is one of the most common ophthalmic conditions, affecting hundreds of millions of people worldwide. Recent technological advances and research targeting DED have led to the emergence of new definitions and…
Eyenovia Pediatric Myopia Trial Falls Short
Eyenovia has announced that its Phase 3 CHAPERONE study, aimed at treating pediatric progressive myopia, failed to meet its primary endpoint. The trial evaluated the company’s proprietary drug-device combination using low-dose atropine delivered via the Optejet platform. A review by…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…
Atsena & Nippon Shinyaku Partner on ATSN-101
Atsena Therapeutics, Inc. and Nippon Shinyaku Co., Ltd. have entered an exclusive licensing agreement to advance and commercialize ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), in both the United States and Japan. ATSN-101 is designed…
Harrow Gains Medicare Part D Access for Vevye in 2025
Harrow has announced that its dry eye disease treatment, Vevye, will be added to the formularies of key Medicare Part D plan sponsors starting January 1, 2025. Major plan sponsors including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark, which…
Top 15 International Ophthalmology Congresses in 2024
As the field of ophthalmology continues to advance, a plethora of international congresses offer opportunities for professionals to explore the latest innovations, share insights, and foster collaborations. Here is a comprehensive list of the top 15 international ophthalmology conferences scheduled…
What Is Ophthalmia Neonatorum? | OBN
Ophthalmia neonatorum, also known as neonatal conjunctivitis, is an inflammation of the conjunctiva (the clear membrane covering the white part of the eye) that occurs in newborns. It is a serious condition that can lead to blindness if left untreated.…